Johnson & Johnson (JNJ)
| Market Cap | 365.65B |
| Revenue (ttm) | 88.82B |
| Net Income (ttm) | 14.07B |
| Shares Out | 2.41B |
| EPS (ttm) | 5.79 |
| PE Ratio | 26.21 |
| Forward PE | 14.43 |
| Dividend | $4.96 (3.27%) |
| Ex-Dividend Date | Feb 18, 2025 |
| Volume | 6,898,322 |
| Open | 150.37 |
| Previous Close | 148.69 |
| Day's Range | 148.19 - 152.35 |
| 52-Week Range | 140.68 - 169.99 |
| Beta | 0.48 |
| Analysts | Buy |
| Price Target | 170.18 (+12.16%) |
| Earnings Date | Apr 15, 2025 |
About JNJ
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizo... [Read more]
Financial Performance
In 2024, Johnson & Johnson's revenue was $88.82 billion, an increase of 4.30% compared to the previous year's $85.16 billion. Earnings were $14.07 billion, a decrease of -59.99%.
Financial StatementsAnalyst Forecast
According to 18 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price forecast is $170.18, which is an increase of 12.16% from the latest price.
News
Jim Cramer's week ahead: Earnings from Goldman Sachs, Johnson & Johnson and Netflix
CNBC's Jim Cramer on Friday told investors which market-moving events to follow next week. He pinpointed earnings reports from major banks like Goldman Sachs, as well as Johnson & Johnson and Netflix,
Johnson & Johnson: Fairly Valued, But Recession-Resilient
Johnson & Johnson offers stability and limited downside risk, making it a solid investment in volatile markets, despite not being a high-growth stock. The company's fiscal 2024 results showed moderate...
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told...
Icotrokinra results show 75% of adolescents with plaque psoriasis achieved completely clear skin and demonstrate favorable safety profile in a once daily pill
ICONIC-LEAD is the first ever Phase 3 registrational study in moderate-to-severe plaque psoriasis to assess safety and efficacy of a systemic therapy in adolescents and adults simultaneously 84% of ad...
Autos, pharma, luxury and more: The global sectors soaring after Trump's tariffs walkback
European stocks soared on Thursday after U.S. President Donald Trump's jarring about-turn on most tariffs. Tensions between Washington and Beijing remain high, however, with Trump ratcheting up duties...
BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks
Evan Seigerman, BMO, joins 'Fast Money' to talk the impact of tariffs on pharma space.
Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out
The Trump administration's proposed tariffs on pharmaceuticals have caused significant market turmoil today, with major Pharma stocks plummeting globally. Despite pledges to increase U.S. manufacturin...
Explainer: Prescription drugs become a target in Trump's trade war
U.S. President Donald Trump late on Tuesday reiterated he would impose tariffs on imports of pharmaceutical products that have long been spared from past trade disputes due to the potential for harm t...
Pharmaceutical stocks fall as Trump doubles down on tariffs threat
Pharmaceutical stocks fell after President Donald Trump doubled down on plans to impose tariffs on pharmaceuticals imported into the U.S. "very shortly." Shares of Eli Lilly, AbbVie, Bristol Myers Squ...
Why drug stocks are no longer a safe haven from the stock market's turmoil
Shares of drugmakers were taking a broad beating Wednesday, after President Donald Trump indicated that pharmaceuticals will no longer be excluded from tariffs.
This Johnson & Johnson Analyst Turns Bullish On Shifting Focus From Stelara Concerns To Innovative Medicine
While the consensus seems to underappreciate the trajectory of Johnson & Johnson's JNJ Innovative Medicine business, Goldman Sachs says concerns around the Stelara loss of exclusivity appear overdone.
S&P 500: Pharma Giants Lead Decline as Tariff Threats Rattle Pfizer, Merck, Johnson & Johnson
Pharmaceutical stocks tumble as Trump announces imminent “major tariff” on imported drugs. Pfizer, Merck, and Johnson & Johnson shares drop over 4%, dragging the broader S&P 500 lower.
Cramer's Stop Trading: Johnson & Johnson
Jim Cramer breaks down why he's keeping an eye on shares of Johnson & Johnson.
Johnson & Johnson highlights new data, demonstrating long-term sustained disease control in adults living with generalised myasthenia gravis (gMG)
New compelling results demonstrate 18 months of both sustained reduction in immunoglobulin G antibodies and sustained improvement in gMG symptoms in pivotal Vivacity-MG3 study and open label extension...
Johnson & Johnson highlights new data that showcase the strength of nipocalimab, demonstrating long-term sustained disease control in adults living with generalized myasthenia gravis (gMG)
New compelling results demonstrate 18 months of both sustained reduction in immunoglobulin G antibodies and sustained improvement in gMG symptoms in pivotal Vivacity-MG3 study and open-label extension...
Johnson & Johnson to Participate in the BofA Securities 2025 Healthcare Conference
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the BofA Securities 2025 Healthcare Conference on Tuesday, May 13th, 2025. Management will participate in a Fireside...
Market Weakness, A.I. Frenzy & Rebecca Walser's Picks: META, TTD, JNJ
Rebecca Walser (@walserwealth) joins Nicole Petallides at the NYSE desk to discuss her Sep. 2024 call for a 30% pullback in the stock market. She explains her rationale and examines bigger trends in t...
European Commission approves Johnson & Johnson's subcutaneous DARZALEX® (daratumumab)-based quadruplet regimen for the treatment of patients with newly diagnosed multiple myeloma, regardless of transplant eligibility
Approval cements daratumumab as a foundational therapy in newly diagnosed multiple myeloma and the only anti-CD38 antibody for all patient types in this setting
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (April 2025)
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. The market is volatil...
TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to significantly reduce both the signs and symptoms and the progression of structural damage in adults living with active psoriatic arthritis
TREMFYA® demonstrated clinically meaningful and statistically significant efficacy in patients with active psoriatic arthritis at risk for structural damage in Phase 3b study Topline results demonstra...
Potatoes, discount chains and drugmakers offer havens in stock-market bloodbath
Potato maker Lamb Weston Holdings Inc., telecom giant Verizon Communications Inc., drug maker AbbVie Inc. and retailer TJX Cos. all bucked a sharp market selloff Thursday, as Wall Street turned to sto...
Stock Of The Day: Will Johnson & Johnson Rally? The Sell-Off May Have Ended
Shares of Johnson & Johnson JNJ are trading higher on Wednesday. Yesterday, they were down more than 7.5%.